Descárgate aquí la Guía Dislipemias 2016
Publicaciones Similares
Video resumen de la Jornada Lipid Expert Day
PorSadenoEn el siguiente video podrá ver un completo resumen de la Jornada Lipid Expert Day, celebrada e pasado 6 de junio en el Palacio de Congresos y Exposiciones Ciudad de Oviedo. Durante la Jornada se analizaron temas de diversa índole como, Técnicas de imagen para valoración de la aterosclerosis; que corrió a cargo del Dr. Leopoldo Pérez…
Artículo Tiroides y embarazo y posparto
PorSadenoEstá disponible para descarga el artículo sobre Diagnosis and Management of Thyroid Disease during Pregnancy and the Postpartum, de la Asociación Americana de Tiroides. Descárgalo aquí
Evolocumab and Clinical Outcomes in Patients with Card. Disease
PorSadenoDescargue el artículo completo ABSTRACT BACKGROUND Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it prevents cardiovascular events is uncertain. METHODS We conducted a randomized, double-blind, placebo-controlled trial involving 27,564 patients with atherosclerotic cardiovascular disease and LDL cholesterol levels…
Artículo Diamond Study Group
PorSadenoEstá disponible para descarga el artículo Effect of Continuous Glucose Monitoring on Glycemic Control in Adults with Type 1 Diabetes Using Insulin Injections. Autores: RoyW. Beck, MD, PhD; Tonya Riddlesworth, PhD; Katrina Ruedy, MSPH; Andrew Ahmann, MD; Richard Bergenstal, MD; Stacie Haller, RD, LD, CDE; Craig Kollman, PhD; Davida Kruger, MSN, APN-BC; Janet B….
Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM–INSULIN trial
PorSadenoConsulta aquí el artículo: Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM–INSULIN trial
AACE/ACE Consensus Statement
PorSadenoCONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2017 EXECUTIVE SUMMARY Autores: Alan J. Garber, MD, PhD, FACE1; Martin J. Abrahamson, MD2; Joshua I. Barzilay, MD, FACE3; Lawrence Blonde, MD, FACP, FACE4; Zachary T. Bloomgarden, MD, MACE5; Michael A. Bush, MD6; Samuel…
